Aadi Bioscience is a biopharmaceutical company focused on developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Co.'s primary drug product, FYARRO, is a form of sirolimus bound to albuminnab. Co. is studying FYARRO in cancers with known mTOR pathway activation, including tumor-agnostic indications targeting specific genomic alterations that activate the mTOR pathway. In addition, Co. has ongoing studies as well as studies in planning for testing the safety and efficacy of FYARRO in combination with other targeted agents, such as Co.'s exisitng collaboration with Mirati Therapeutics, Inc. We show 10 historical shares outstanding datapoints in our AADI shares outstanding history coverage, used to compute AADI market cap on those dates.
Understanding the changing numbers of shares outstanding, the changing
share price, and the resulting changing AADI market cap history over the course of time is important for investors
interested in comparing AADI's market cap history versus its peers.
Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies,
and then calculating their respective market caps. Comparing the share price of AADI versus a peer is one thing; comparing
AADI market cap versus a peer is a completely different story.
Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares),
the market cap for a company like AADI can fluctuate over the course of history.
With this page we aim to empower investors researching AADI by allowing them to research the AADI market cap history. |
Free AADI Email Alerts:
Video: The Importance of Market Cap
